Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Richard A, Koup"'
Autor:
Jeffrey D. Lifson, John R. Mascola, Sean P. O’Brien, Theodora Hatziioannou, Paul D. Bieniasz, Jason Gorman, Brandon F. Keele, George M. Shaw, Gregory Q. Del Prete, Richard A. Koup, Taina T. Immonen, Adrienne E. Swanstrom, Christine M. Fennessey, Amarendra Pegu, Kathryn E. Foulds, Nicole A. Doria-Rose, Peter D. Kwong, Sung-Youl Ko, Mario Roederer, Carolyn Williamson, Stephen D. Schmidt, Hui Li
Publikováno v:
PLoS Pathogens
PLoS Pathogens, Vol 15, Iss 4, p e1007632 (2019)
PLoS Pathogens, Vol 15, Iss 4, p e1007632 (2019)
Chimeric Simian-Human Immunodeficiency Viruses (SHIVs) are an important tool for evaluating anti-HIV Env interventions in nonhuman primate (NHP) models. However, most unadapted SHIVs do not replicate well in vivo limiting their utility. Furthermore,
Autor:
Mario Roederer, Salim S. Abdool Karim, Koleka Mlisana, Clive M. Gray, Richard A. Koup, Catherine Riou, Carolyn Williamson, Wendy A. Burgers
Publikováno v:
Journal of Virology. 88:1819-1824
Defining the characteristics of HIV-specific CD8 + T cell responses that lead to viral control is crucial for vaccine development. We evaluated the differential impact of magnitude, polyfunctional capacity, and specificity of the CD8 + response at ap
Autor:
Marlous L. Grijsen, John R. Mascola, Rebecca M. Lynch, Adam K. Wheatley, Jan M. Prins, Richard A. Koup, Madhu Prabhakaran, Godelieve J. de Bree, Adrian B. McDermott, Stephen D. Schmidt
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 3, p e0173577 (2017)
PLoS ONE, 12(3). Public Library of Science
PLoS ONE, Vol 12, Iss 3, p e0173577 (2017)
PLoS ONE, 12(3). Public Library of Science
Background Neutralizing antibodies develop in natural HIV-1 infection. Their development often takes several years and may rely on chronic virus exposure. At the same time recent studies show that treatment early in infection may provide opportunitie
Autor:
S. Munir Alam, Guido Ferrari, Thomas N. Denny, Stephen D. Schmidt, Mark K. Louder, Brandy M. Ward, Norman L. Letvin, Hugh C. Welles, Rosemarie D. Mason, Ling Shen, Celia C. LaBranche, Raphael Gottardo, Kathryn E. Foulds, Kelly E. Seaton, Martha Nason, Robert T. Bailer, Robert A. Seder, Will Fischer, Linh Mach, Mario Roederer, John R. Mascola, Georgia D. Tomaras, Bette T. Korber, Srinivas S. Rao, John Paul Todd, Brandon F. Keele, Adam P. Buzby, Gary J. Nabel, Richard A. Koup, Zhi-Yong Yang, David C. Montefiori, Wenjuan Gu
Publikováno v:
Nature
A major challenge for the development of a highly effective AIDS vaccine is the identification of mechanisms of protective immunity. To address this question, we used a nonhuman primate challenge model with simian immunodeficiency virus (SIV). We sho
Autor:
Julie E. Ledgerwood, Raphael Gottardo, David Price, Emily C. Smith, Robert T. Bailer, Deborah Persaud, Frank Maldarelli, Emma Gostick, Charla A. Andrews, Ingelise J. Gordon, Barney S. Graham, Martha Nason, Mario Roederer, Ann Wiegand, Selorm Adzaku, Mary F. Kearney, David R. Ambrozak, Richard A. Koup, Joseph P. Casazza, Kathryn Bowman, Mary E. Enama, Carrie Ziemniak
Publikováno v:
The Journal of Infectious Diseases. 207:1829-1840
Background. The licensing of herpes zoster vaccine has demonstrated that therapeutic vaccination can help control chronic viral infection. Unfortunately, human trials of immunodeficiency virus (HIV) vaccine have shown only marginal efficacy.Methods.
Autor:
Pascal Poignard, Paul W. H. I. Parren, Richard A. Koup, Marie Claire Gauduin, Dennis R. Burton, Paola Fisicaro, Quentin J. Sattentau
Understanding the antibody response in HIV-1 infection is important to vaccine design. We have studied the antibody response to HIV-1 envelope at the molecular level and determined the characteristics of neutralizing and non-neutralizing antibodies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af5e0cdb79453b986977d08c0052412b
https://doi.org/10.1016/s0165-2478(97)00043-6
https://doi.org/10.1016/s0165-2478(97)00043-6
Autor:
Timothy J. Wilkin, Philip L. Felgner, Johannes S. Gach, Chase T. M. Anderson, Steven G. Deeks, Christine Katlama, Donald N. Forthal, Andrea Gorlani, Chad J. Achenbach, Brigitte Autran, Richard A. Koup, Emmanuel Y. Dotsey, Joseph P. Casazza, Baiba Berzins, Juan C. Becerra, Robert L. Murphy
Publikováno v:
PLoS ONE, Vol 11, Iss 8, p e0160341 (2016)
PLoS ONE
PloS one, vol 11, iss 8
PLoS ONE
PloS one, vol 11, iss 8
Little is known about the humoral immune response against DNA prime-recombinant adenovirus 5 (rAd5) boost HIV vaccine among HIV-infected patients on long-term suppressive antiretroviral therapy (ART). Previous studies emphasized cellular immune respo
Optimal Antigens for HIV Vaccines Based on CD8+ T Response, Protein Length, and Sequence Variability
Publikováno v:
DNA and Cell Biology. 21:665-670
The identification of optimal antigens to include in an HIV vaccine designed to elicit a cellular immune response requires careful consideration of protein length, variability, and immunogenicity. Here, we have examined the relationship of these para
Autor:
Richard A. Koup, Constantinos Petrovas
Publikováno v:
Current opinion in HIV and AIDS. 9(3)
Here, we describe recent data on the characterization of follicular helper CD4 T cells (Tfh) and the dynamics of Tfh-B-cell interactions in HIV and simian immunodeficiency virus (SIV) infection and discuss important aspects of these interactions that
Autor:
Scott M, Hammer, Magdalena E, Sobieszczyk, Holly, Janes, Shelly T, Karuna, Mark J, Mulligan, Doug, Grove, Beryl A, Koblin, Susan P, Buchbinder, Michael C, Keefer, Georgia D, Tomaras, Nicole, Frahm, John, Hural, Chuka, Anude, Barney S, Graham, Mary E, Enama, Elizabeth, Adams, Edwin, DeJesus, Richard M, Novak, Ian, Frank, Carter, Bentley, Shelly, Ramirez, Rong, Fu, Richard A, Koup, John R, Mascola, Gary J, Nabel, David C, Montefiori, James, Kublin, M Juliana, McElrath, Lawrence, Corey, Peter B, Gilbert, Michael T, Yin
Publikováno v:
The New England journal of medicine. 369(22)
A safe and effective vaccine for the prevention of human immunodeficiency virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime-recombinant adenovirus type 5 boost (DNA/rAd5) vaccine regimen in persons at increase